Filtered By:
Source: European Heart Journal
Condition: Stroke

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 328 results found since Jan 2013.

Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study
Conclusion The heterogeneity in the risk factor–CVD associations supports the concept of pathophysiological differences between atherosclerotic CVD manifestations and could have implications for CVD prevention.
Source: European Heart Journal - March 14, 2016 Category: Cardiology Authors: Stoekenbroek, R. M., Boekholdt, S. M., Luben, R., Hovingh, G. K., Zwinderman, A. H., Wareham, N. J., Khaw, K.-T., Peters, R. J. G. Tags: Prevention and epidemiology Source Type: research

Coping strategies and risk of cardiovascular disease incidence and mortality: the Japan Public Health Center-based prospective Study
Conclusion An approach-oriented coping strategy, i.e. proactively dealing with sources of stress, may be associated with significantly reduced stroke incidence and CVD mortality in a Japanese population-based cohort.
Source: European Heart Journal - March 14, 2016 Category: Cardiology Authors: Svensson, T., Inoue, M., Sawada, N., Yamagishi, K., Charvat, H., Saito, I., Kokubo, Y., Iso, H., Kawamura, N., Shibuya, K., Mimura, M., Tsugane, S., for the JPHC Study Group, for the JPHC Study Group, Tsugane, Tsugane, Sawada, Iwasaki, Sasazuki, Shimazu, Tags: Prevention and epidemiology Source Type: research

The future of transcatheter aortic valve implantation
Since the introduction of transcatheter aortic valve implantation (TAVI) into clinical practice, the treatment of aortic stenosis has changed dramatically. In the past, medical therapy with or without balloon aortic valvuloplasty was the only option for inoperable patients. More recently, TAVI has become the treatment of choice for these patients and the preferred alternative for high-risk operable patients. Surgical aortic valve replacement (SAVR) currently remains the gold standard for patients at low or intermediate operative risk. As randomized trials have demonstrated comparable results between TAVI and SAVR in the hi...
Source: European Heart Journal - March 7, 2016 Category: Cardiology Authors: Hamm, C. W., Arsalan, M., Mack, M. J. Tags: Frontiers in cardiovascular medicine Source Type: research

Left ventricular systolic function assessment in secondary mitral regurgitation: left ventricular ejection fraction vs. speckle tracking global longitudinal strain
Conclusion In patients with severe secondary MR, speckle-tracking GLS shows more deteriorated LV systolic function than LVEF.
Source: European Heart Journal - March 7, 2016 Category: Cardiology Authors: Kamperidis, V., Marsan, N. A., Delgado, V., Bax, J. J. Tags: Valvular heart disease Source Type: research

Transcatheter treatment of severe tricuspid regurgitation with the MitraClip system
Conclusions Transcatheter tricuspid valve repair by use of interventional edge-to-edge repair with the MitraClip system was feasible, and safe in three consecutive patients. Reduction of tricuspid insufficiency associates with relief of clinical symptoms for right heart failure. This strategy seems a promising treatment option for patients at prohibitive surgical risk.
Source: European Heart Journal - March 7, 2016 Category: Cardiology Authors: Hammerstingl, C., Schueler, R., Malasa, M., Werner, N., Nickenig, G. Tags: EHJ BRIEF COMMUNICATION Source Type: research

Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation
Conclusion</strong> Left atrial appendage closure in NVAF in a real-world setting may result in lower stroke and major bleeding rates than reported in LAAC clinical trials. Left atrial appendage closure in both settings achieves cost parity in a relatively short period of time and may offer substantial savings compared with current therapies. Savings are most pronounced among higher risk patients and those unsuitable for anticoagulation.</span>
Source: European Heart Journal - February 29, 2016 Category: Cardiology Source Type: research

CardioPulse Articles * Gerhard Hindricks MD * Cardiac Centres Of Excellence * Leipzig Heart Centre - Department of Electrophysiology * New perspectives for stroke prevention in atrial fibrillation * Syncope and near drowning may signal sudden death risk * Ear stimulation for atrial fibrillation favoured at ESC Congress London
Source: European Heart Journal - February 14, 2016 Category: Cardiology Tags: CardioPulse Source Type: research

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1
<span class="paragraphSection">Patients with atrial fibrillation (AF) have a high risk of stroke and mortality, which can be considerably reduced by oral anticoagulants (OAC). Recently, four non-vitamin-K oral anticoagulants (NOACs) were compared with warfarin in large randomized trials for the prevention of stroke and systemic embolism. Today's clinician is faced with the difficult task of selecting a suitable OAC for a patient with a particular clinical profile or a particular pattern of risk factors and concomitant diseases. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs. NOA...
Source: European Heart Journal - February 4, 2016 Category: Cardiology Source Type: research

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2
<span class="paragraphSection">The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be influenced by individual clinical features or by patterns of risk factors and comorbidities. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs. non-vitamin K oral anticoagulants (NOACs) for stroke prevention in AF with the aim to identify patient groups who might benefit from a particular OAC more than from another. In addition, we discuss the timing of initiation of anticoagulation. In the second of a two-part review, we discuss the use of NOAC for stroke prevent...
Source: European Heart Journal - February 4, 2016 Category: Cardiology Source Type: research

Coronary microcirculatory pathophysiology: can we afford it to remain a black box?
<span class="paragraphSection"><div class="boxTitle">Abstract</div>Coronary microvascular networks play the key role in determining blood flow distribution in the heart. Matching local blood supply to tissue metabolic demand entails continuous adaptation of coronary vessels via regulation of smooth muscle tone and structural dilated vessel diameter. The importance of coronary microcirculation for relevant pathological conditions including angina in patients with normal or near-normal coronary angiograms [microvascular angina (MVA)] and heart failure with preserved ejection fraction (HFpEF) is increasingly...
Source: European Heart Journal - February 1, 2016 Category: Cardiology Source Type: research

Heart failure: when form fails to follow function
Cardiac performance is normally determined by architectural, cellular, and molecular structures that determine the heart's form, and by physiological and biochemical mechanisms that regulate the function of these structures. Impaired adaptation of form to function in failing hearts contributes to two syndromes initially called systolic heart failure (SHF) and diastolic heart failure (DHF). In SHF, characterized by high end-diastolic volume (EDV), the left ventricle (LV) cannot eject a normal stroke volume (SV); in DHF, with normal or low EDV, the LV cannot accept a normal venous return. These syndromes are now generally de...
Source: European Heart Journal - February 1, 2016 Category: Cardiology Authors: Katz, A. M., Rolett, E. L. Tags: Clinical update Source Type: research

Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial
Conclusions Extended DAPT did not achieve superiority in reducing net adverse clinical events compared to 12 months of DAPT after DES placement. The power of the OPTIDUAL trial was however low and reduced by premature termination of enrolment. ClinicalTrials.gov number NCT00822536.
Source: European Heart Journal - January 21, 2016 Category: Cardiology Authors: Helft, G., Steg, P. G., Le Feuvre, C., Georges, J.-L., Carrie, D., Dreyfus, X., Furber, A., Leclercq, F., Eltchaninoff, H., Falquier, J.-F., Henry, P., Cattan, S., Sebagh, L., Michel, P.-L., Tuambilangana, A., Hammoudi, N., Boccara, F., Cayla, G., Douard, Tags: ESC Hot Line Source Type: research

Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials
Conclusion Compared with aspirin alone, DAPT beyond 1 year among stabilized high-risk patients with prior MI decreases ischaemic events, including significant reductions in the individual endpoints of cardiovascular death, recurrent MI, and stroke. Dual antiplatelet therapy beyond 1 year increases major bleeding, but not fatal bleeding or non-cardiovascular death.
Source: European Heart Journal - January 21, 2016 Category: Cardiology Authors: Udell, J. A., Bonaca, M. P., Collet, J.-P., Lincoff, A. M., Kereiakes, D. J., Costa, F., Lee, C. W., Mauri, L., Valgimigli, M., Park, S.-J., Montalescot, G., Sabatine, M. S., Braunwald, E., Bhatt, D. L. Tags: Coronary artery disease Source Type: research

Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial
Conclusion In patients with a history of MI, patients with renal dysfunction are at increased risk of MACE and consequently experience a particularly robust absolute risk reduction with long-term treatment with ticagrelor.
Source: European Heart Journal - January 21, 2016 Category: Cardiology Authors: Magnani, G., Storey, R. F., Steg, G., Bhatt, D. L., Cohen, M., Kuder, J., Im, K., Aylward, P., Ardissino, D., Isaza, D., Parkhomenko, A., Goudev, A. R., Dellborg, M., Kontny, F., Corbalan, R., Medina, F., Jensen, E. C., Held, P., Braunwald, E., Sabatine, Tags: Thrombosis and antithrombotic therapy Source Type: research

Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome
Conclusions Neoplasm events were infrequent during long-term DAPT after ACS, were associated with differential cancer-screening practices across regions, and the frequency of neoplasm detection was similar with prasugrel vs. clopidogrel. Trial registration ClinicalTrials.gov identifier: NCT00699998.
Source: European Heart Journal - January 21, 2016 Category: Cardiology Authors: Roe, M. T., Cyr, D. D., Eckart, D., Schulte, P. J., Morse, M. A., Blackwell, K. L., Ready, N. E., Zafar, S. Y., Beaven, A. W., Strickler, J. H., Onken, J. E., Winters, K. J., Houterloot, L., Zamoryakhin, D., Wiviott, S. D., White, H. D., Prabhakaran, D., Tags: Acute coronary syndromes Source Type: research